Matthew Stenger

6 days ago | ascopost.com | Matthew Stenger

In a pooled analysis of the phase II TRUST-I and TRUST-II trials reported in the Journal of Clinical Oncology, Pérol et al found that the oral, potent, CNS-active, selective, next-generation ROS1 tyrosine kinase inhibitor (TKI) taletrectinib was highly active in ROS1-positive advanced or metastatic non–small cell lung cancer (NSCLC). Study DetailsTRUST-I was a Chinese study with two cohorts: TKI-naive patients and patients in whom previous crizotinib failed.

6 days ago | ascopost.com | Matthew Stenger

In a pooled analysis of the phase II TRUST-I and TRUST-II trials reported in the Journal of Clinical Oncology, Pérol et al found that the oral, potent, CNS-active, selective, next-generation ROS1 tyrosine kinase inhibitor (TKI) taletrectinib was highly active in ROS1-positive advanced or metastatic non–small cell lung cancer (NSCLC). Study DetailsTRUST-I was a Chinese study with two cohorts: TKI-naive patients and patients in whom previous crizotinib failed.

1 week ago | ascopost.com | Matthew Stenger

In an analysis from the phase III RATIONALE-302 trial reported in the Journal of Clinical Oncology, Lu et al found that the presence of NOTCH1 mutation was associated with improved overall survival in patients receiving second-line tislelizumab vs investigator’s choice of chemotherapy for advanced or metastatic esophageal squamous cell carcinoma.

1 week ago | ascopost.com | Matthew Stenger

In the French phase II PANACHE01-PRODIGE48 trial, researchers found that neoadjuvant chemotherapy with mFOLFIRINOX (modified leucovorin, fluorouracil, irinotecan, and oxaliplatin) was feasible and active in patients with resectable pancreatic adenocarcinoma. Schwarz et al published these findings in the Journal of Clinical Oncology.

1 week ago | ascopost.com | Matthew Stenger

In a UK phase III trial (UKALL 2011) reported in the Journal of Clinical Oncology, Kirkwood et al found that a shorter duration of induction dexamethasone did not reduce steroid-related toxicity and that high-dose methotrexate (HDM) did not reduce central nervous system (CNS) relapse among patients younger than age 25 with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma.